CN109563034A - 化学化合物 - Google Patents

化学化合物 Download PDF

Info

Publication number
CN109563034A
CN109563034A CN201780045519.3A CN201780045519A CN109563034A CN 109563034 A CN109563034 A CN 109563034A CN 201780045519 A CN201780045519 A CN 201780045519A CN 109563034 A CN109563034 A CN 109563034A
Authority
CN
China
Prior art keywords
chlorophenoxy
disease
acetamide
methyl
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780045519.3A
Other languages
English (en)
Chinese (zh)
Inventor
J.阿克斯滕
M.张
A.W.迪安
M.P.德马蒂诺
H.S.艾达姆
R.R.克西里
B.卡利塔
R.克里斯塔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN109563034A publication Critical patent/CN109563034A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CN201780045519.3A 2016-06-08 2017-06-07 化学化合物 Pending CN109563034A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201611019696 2016-06-08
IN201611019696 2016-06-08
PCT/IB2017/053370 WO2017212423A1 (en) 2016-06-08 2017-06-07 Chemcical compounds

Publications (1)

Publication Number Publication Date
CN109563034A true CN109563034A (zh) 2019-04-02

Family

ID=59101532

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780045519.3A Pending CN109563034A (zh) 2016-06-08 2017-06-07 化学化合物

Country Status (10)

Country Link
US (1) US10851053B2 (https=)
EP (1) EP3468948A1 (https=)
JP (1) JP2019521109A (https=)
KR (1) KR20190015492A (https=)
CN (1) CN109563034A (https=)
AU (1) AU2017279027A1 (https=)
BR (1) BR112018075615A2 (https=)
CA (1) CA3026983A1 (https=)
RU (1) RU2018146946A (https=)
WO (1) WO2017212423A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113993850A (zh) * 2019-04-23 2022-01-28 埃沃特克国际有限责任公司 整合应激反应途径的调节剂
CN116332818A (zh) * 2021-12-22 2023-06-27 王喆明 四氢吡咯衍生物及其应用
CN116751147A (zh) * 2023-06-28 2023-09-15 深圳市茵诺圣生物科技有限公司 一种5-氨甲基-2-吡咯烷酮的合成方法
CN116789888A (zh) * 2023-05-04 2023-09-22 浙江大学 一种能够减轻器官缺血再灌注损伤的抗自由基聚合物及其制备方法和用途
CN117062817A (zh) * 2021-01-13 2023-11-14 斯瑞福治疗股份有限公司 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118239937A (zh) 2017-08-09 2024-06-25 戴纳立制药公司 化合物、组合物及方法
DK3676297T3 (da) 2017-09-01 2023-08-14 Denali Therapeutics Inc Forbindelser, sammensætninger og fremgangsmåder
WO2019118785A2 (en) 2017-12-13 2019-06-20 Praxis Biotech LLC Inhibitors of integrated stress response pathway
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
WO2019183589A1 (en) * 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193540A1 (en) * 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
US11253522B2 (en) 2018-04-28 2022-02-22 The Regents Of The University Of California Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
WO2019236710A1 (en) * 2018-06-05 2019-12-12 Praxis Biotech LLC Inhibitors of integrated stress response pathway
WO2020031107A1 (en) * 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
MA54953A (fr) * 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
CN120097859A (zh) * 2019-02-19 2025-06-06 加利福尼亚大学董事会 Nurr1受体调节剂
US20200270232A1 (en) * 2019-02-25 2020-08-27 Praxis Biotech LLC Inhibitors of integrated stress response pathway
MX2021012904A (es) 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
AU2021213289A1 (en) 2020-01-28 2022-07-07 Evotec International Gmbh Modulators of the integrated stress response pathway
MX2022011143A (es) 2020-03-11 2022-10-13 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
US20230391763A1 (en) 2020-10-22 2023-12-07 Evotec International Gmbh Modulators of the integrated stress response pathway
JP2023546224A (ja) 2020-10-22 2023-11-01 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合ストレス応答経路のモジュレーター
MX2023004623A (es) 2020-10-22 2023-05-12 Evotec Int Gmbh Moduladores de la via integrada de respuesta al estres.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1179341A1 (en) * 1999-05-18 2002-02-13 Teijin Limited Remedies or preventives for diseases in association with chemokines
US20050234034A1 (en) * 2004-03-03 2005-10-20 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20060019985A1 (en) * 2004-07-22 2006-01-26 Cumbre Inc. Rifamycin derivatives
US20080207648A1 (en) * 2005-01-14 2008-08-28 Robin Alec Fairhurst Organic Compounds
WO2008150231A1 (en) * 2007-06-08 2008-12-11 Astrazeneca Ab New heterocyclic compounds for treatment of respiratory, airway or inflammatory disorders
WO2013065712A1 (ja) * 2011-10-31 2013-05-10 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
US20160096800A1 (en) * 2013-03-15 2016-04-07 The Regents Of The University Of California Modulators of the eif2alpha pathway

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6515013B2 (en) * 2000-07-13 2003-02-04 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
JP2002105073A (ja) * 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
BR0116452A (pt) 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
SE0100326D0 (sv) 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
HRP20040805A2 (en) 2002-03-13 2005-04-30 Janssen Pharmaceutica N.V. Carbonylamino derivatives as novel inhibitors histone deacetylase
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US7338975B2 (en) * 2003-02-12 2008-03-04 Bristol-Myers Squibb Co. Lactams as modulators of chemokine receptor activity
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
MX2009011342A (es) * 2007-04-20 2009-11-05 Invista Tech Sarl Fileta compacta de desenrollamiento continuo por encima con control de tension.
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
JP2010095453A (ja) * 2008-10-14 2010-04-30 Kaneka Corp 光学活性１−アリール−３−ピロリジノールの製造法
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
JP6006794B2 (ja) * 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド 核内輸送調節因子およびその使用
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
JP5799117B2 (ja) * 2013-02-05 2015-10-21 大日本住友製薬株式会社 ウラシル誘導体からなる医薬
US20160318856A1 (en) * 2013-09-11 2016-11-03 The Brigham And Women's Hospital, Inc. Substituted Urea eIF2alpha Kinase Activators
CA2936886A1 (en) 2014-02-27 2015-08-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1179341A1 (en) * 1999-05-18 2002-02-13 Teijin Limited Remedies or preventives for diseases in association with chemokines
US20050234034A1 (en) * 2004-03-03 2005-10-20 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20060019985A1 (en) * 2004-07-22 2006-01-26 Cumbre Inc. Rifamycin derivatives
US20080207648A1 (en) * 2005-01-14 2008-08-28 Robin Alec Fairhurst Organic Compounds
WO2008150231A1 (en) * 2007-06-08 2008-12-11 Astrazeneca Ab New heterocyclic compounds for treatment of respiratory, airway or inflammatory disorders
WO2013065712A1 (ja) * 2011-10-31 2013-05-10 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
US20160096800A1 (en) * 2013-03-15 2016-04-07 The Regents Of The University Of California Modulators of the eif2alpha pathway

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACS.REGISTRY DATABASE: "D7", 《STNEXT》 *
BRIAN R. HEARN ET AL.: "Structure–Activity Studies of Bis-O-Arylglycolamides:Inhibitors of the Integrated Stress Response", 《CHEMMEDCHEM》 *
DAVID M. ROTSTEIN ET AL.: "Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
SVEN P. FRITZ ET AL.: "Efficient Synthesis of Cyclopropane-Fused Heterocycles with Bromoethylsulfonium Salt", 《CHEMISTRY A EUROPEAN JOURNAL》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113993850A (zh) * 2019-04-23 2022-01-28 埃沃特克国际有限责任公司 整合应激反应途径的调节剂
CN113993850B (zh) * 2019-04-23 2024-03-29 埃沃特克国际有限责任公司 整合应激反应途径的调节剂
CN117062817A (zh) * 2021-01-13 2023-11-14 斯瑞福治疗股份有限公司 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物
CN116332818A (zh) * 2021-12-22 2023-06-27 王喆明 四氢吡咯衍生物及其应用
CN116332818B (zh) * 2021-12-22 2023-12-15 王喆明 四氢吡咯衍生物及其应用
CN116789888A (zh) * 2023-05-04 2023-09-22 浙江大学 一种能够减轻器官缺血再灌注损伤的抗自由基聚合物及其制备方法和用途
CN116789888B (zh) * 2023-05-04 2025-11-18 浙江大学 一种能够减轻器官缺血再灌注损伤的抗自由基聚合物及其制备方法和用途
CN116751147A (zh) * 2023-06-28 2023-09-15 深圳市茵诺圣生物科技有限公司 一种5-氨甲基-2-吡咯烷酮的合成方法

Also Published As

Publication number Publication date
BR112018075615A2 (pt) 2019-07-02
JP2019521109A (ja) 2019-07-25
US20190144384A1 (en) 2019-05-16
AU2017279027A1 (en) 2018-12-20
CA3026983A1 (en) 2017-12-14
EP3468948A1 (en) 2019-04-17
US10851053B2 (en) 2020-12-01
RU2018146946A (ru) 2020-07-10
KR20190015492A (ko) 2019-02-13
WO2017212423A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
CN109563034A (zh) 化学化合物
CN109563071A (zh) 作为atf4途径抑制剂的化学化合物
JP2020525513A (ja) 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物
BR112020003373A2 (pt) derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
CN109923114A (zh) 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途
WO2018225093A1 (en) Chemical compounds as atf4 pathway inhibitors
CN112424167A (zh) 化学化合物
CN109071447A (zh) 四环吡啶酮化合物作为抗病毒剂
WO2019193540A1 (en) Heteroaryl derivatives of formula (i) as atf4 inhibitors
CN115279771A (zh) Map4k1抑制剂
CN110896634A (zh) 作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物
WO2021115457A1 (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
JP2018527412A (ja) Ｐｅｒｋ阻害剤としての１−フェニルピロリジン−２−オン誘導体
JP2021536436A (ja) キノリン誘導体から調製される新規な阻害剤
AU2014234909A1 (en) Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
CN110730777A (zh) 作为atf4通路抑制剂的化学化合物
CN110248949A (zh) 免疫蛋白酶体抑制剂
HK40047176A (en) Chemical compounds
TW202545941A (zh) 用於緩解疼痛之nav1.8鈉通道之小分子抑制劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190402